BrainsWay/$BWAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BrainsWay
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Ticker
$BWAY
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Jerusalem, Israel
Employees
120
ISIN
US10501L1061
Website
BrainsWay Metrics
BasicAdvanced
$247M
167.01
$0.08
0.08
-
Price and volume
Market cap
$247M
Beta
0.08
52-week high
$13.25
52-week low
$7.84
Average daily volume
45K
Financial strength
Current ratio
5.025
Quick ratio
4.663
Long term debt to equity
7.446
Total debt to equity
8.729
Interest coverage (TTM)
1.33%
Profitability
EBITDA (TTM)
3.239
Gross margin (TTM)
74.51%
Net profit margin (TTM)
9.01%
Operating margin (TTM)
4.31%
Effective tax rate (TTM)
11.78%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
1.42%
Return on equity (TTM)
7.41%
Valuation
Price to earnings (TTM)
167.006
Price to revenue (TTM)
11.225
Price to book
12.82
Price to tangible book (TTM)
12.82
Price to free cash flow (TTM)
60.848
Free cash flow yield (TTM)
1.64%
Free cash flow per share (TTM)
21.73%
Growth
Revenue change (TTM)
26.86%
3-year revenue growth (CAGR)
11.32%
10-year revenue growth (CAGR)
26.84%
3-year earnings per share growth (CAGR)
-28.58%
10-year earnings per share growth (CAGR)
-16.00%
BrainsWay News
AllArticlesVideos
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
GlobeNewsWire·3 weeks ago
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
GlobeNewsWire·3 weeks ago
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BrainsWay stock?
BrainsWay (BWAY) has a market cap of $247M as of June 30, 2025.
What is the P/E ratio for BrainsWay stock?
The price to earnings (P/E) ratio for BrainsWay (BWAY) stock is 167.01 as of June 30, 2025.
Does BrainsWay stock pay dividends?
No, BrainsWay (BWAY) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next BrainsWay dividend payment date?
BrainsWay (BWAY) stock does not pay dividends to its shareholders.
What is the beta indicator for BrainsWay?
BrainsWay (BWAY) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.